Harvard University Researcher Found That Excluding Rare Disease Treatments From Medicare Drug-pricing Pilot Programs Would Eliminate

Biotech companies are lobbying the Trump administration to exempt orphan disease therapies from the Global Benchmark for Efficient Drug Pricing (GLOBE) and Guarding U.S. Medicare Against Rising Drug Costs (GUARD) pilots, part of a most-favored nation policy to align U.S. prices with other wealthy countries. Some drugmakers that struck pricing deals with the White House claim exemptions, though details remain undisclosed.